What important information I should know about Empagliflozin + Linagliptin (Glyxambi®)?

Special warnings and precautions that should be taken into consideration when prescribing Empagliflozin + Linagliptin (Glyxambi®) include:

• Pancreatitis


• Risk of volume depletion


• Genital mycotic infections


• Diabetic Ketoacidosis


• Complicated urinary tract infections


• Hypoglycemia


• Necrotizing fasciitis


• Allergic (hypersensitivity) reactions


• Hypercholesterolemia


• Arthritis


• Bullous pemphigoid

What are the contraindications to Empagliflozin + Linagliptin (Glyxambi®)?

Empagliflozin + Linagliptin (Glyxambi®) should not be used in patients with type 1 diabetes, patients with severe renal impairment and end stage renal disease, those who have hypersensitivity to Empagliflozin or Linagliptin or any of the excipients.

What should I ask my patients before prescribing Empagliflozin + Linagliptin (Glyxambi®)?

Ask your patients if they are currently taking other medications like the following:

• Insulin and sulphonylureas. These may increase the risk of hypoglycaemia. Therefore, a lower dose of insulin or sulphonylureas may be required to reduce the risk of hypoglycaemia when used in combination with Empagliflozin + Linagliptin (Glyxambi®).


• Diuretics. Empagliflozin may add to the diuretic effect of thiazide and loop diuretics and may increase the risk of dehydration and hypotension.


• UGT inhibitors and inducers. Co-medication with known inducers of UGT enzymes should be avoided because of a risk of decreased efficacy of empagliflozin.


• Rifampin. Co-administration of rifampicin decreased linagliptin exposure by 40%, suggesting that the efficacy of linagliptin may be reduced when administered in combination with a strong P-glycoprotein (P-gp) or cytochrome P450 (CYP) isozyme CYP3A4 inducer, particularly if these are administed long-term.

Ask your patients if they are pregnant or planning to be pregnant or are breastfeeding or planning to breastfeed. There are limited data on the use of Empagliflozin + Linagliptin (Glyxambi®) in pregnant women. It is also not known whether the drug is excreted in human milk. As a precautionary measure, it is preferable to avoid the use of Empagliflozin + Linagliptin (Glyxambi®) during pregnancy and breastfeeding.